Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects

Journal of Hypertension

Volumn 24, Issue 10, 2006, Pages 1955-1963

  Rossi, Gian Paolo ^a,d   Taddei, Stefano ^b   Ghiadoni, Lorenzo ^b   Virdis, Agostino ^b   Zavattiero, Silvia ^a   Favilla, Stefania ^b   Versari, Daniele ^b   Sudano, Isabella ^b   Azizi, Michel ^c   Vedie, Benoit ^c   Pessina, Achille C ^a   Salvetti, Antonio ^b   Jeunemaitre, Xavier ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Endothelium; Gene polymorphisms; Hypertension; Nitric oxide; Nitric oxide synthase

Indexed keywords

ACETYLCHOLINE; ARGININE; ASCORBIC ACID; BRADYKININ; HISTIDINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; REACTIVE OXYGEN METABOLITE; TISSUE KALLIKREIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DEMOGRAPHY; ENDOTHELIUM; FEMALE; FOREARM BLOOD FLOW; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENOTYPE; HAPLOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VASODILATATION;

EID: 33748525865     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000244943.34546.40     Document Type: Article

References (31)

1. Luscher TF, Tanner FC, Tschudi MR, Noll G. Endothelial dysfunction in coronary artery disease. Ann Rev Med 1993; 44:395-418.
2. Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DRJ, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101:948-954.
3. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906.
4. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003; 107:2805-2809.
5. Winkelmann BR, Hager J, Kraus WE, Merlini P, Keavney B, Grant PJ, et al. Genetics of coronary heart disease: current knowledge and research principles. Am Heart J 2000; 140:S11-S26.
6. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94:1298-1303.
7. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO III. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995; 91:1732-1738.
8. Taddei S, Ghiadoni L, Virdis A, Buralli S, Salvetti A. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 1999; 100:1400-1405.
9. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23:233-246.
10. Slim R, Torremocha F, Moreau T, Pizard A, Hunt SC, Vuagnat A, et al. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 2002; 13:968-976.
11. Azizi M, Boutouyrie P, Bissery A, Agharazii M, Verbeke F, Stern N, et al. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest 2005; 115:780-787.
12. Campbell DJ. The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 2001; 28:1060-1065.
13. Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci U S A 2001; 98:2634-2639.
14. Berge KE, Bakken A, Bohn M, Erikssen J, Berg K. Analyses of mutations in the human renal kallikrein (hKLK1) gene and their possible relevance to blood pressure regulation and risk of myocardial infarction. Clin Genet 1997; 52:86-95.
15. Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK, Clements JA. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000; 275:37397-37406.
16. Song Q, Chao J, Chao L. DNA polymorphisms in the 5′-flanking region of the human tissue kallikrein gene. Hum Genet 1997; 99:727-734.
17. Berge KE, Berg K. No effect of TaqI polymorphism at the human renal kallikrein (KLK1) locus on normal blood pressure level or variability. Clin Genet 1993; 44:196-202.
18. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23:7-17.
19. Rossi GP, Taddei S, Virdis A, Ghiadoni L, Albertin G, Favilla S, et al. Exclusion of the ACE D/I gene polymorphism as a determinant of endothelial dysfunction. Hypertension 2001; 37:293-300.
20. Rossi GP, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, et al. The T786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 2003; 41:938-945.
21. Rossi GP, Rossi E, Pavan E, Rosati N, Zecchel R, Semplicini A, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998; 49:713-723.
22. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97:2222-2229.
23. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet 2004; 68:165-177.
24. Volianitis S, Secher NH. Arm blood flow and metabolism during arm and combined arm and leg exercise in humans. J Physiol 2002; 544:977-984.
25. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon RO III. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994; 90:35-41.
26. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000; 102:2190-2196.
27. Carretero OA. Vascular remodeling and the kallikrein-kinin system. J Clin Invest 2005; 115:588-591.
28. Griol-Charhbili V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, et al. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 2005; 19:1172-1174.
29. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997; 29:274-279.
30. Wyche KE, Wang SS, Griendling KK, Dikalov SI, Austin H, Rao S, et al. C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 2004; 43:1246-1251.
31. Rossi GP, Cavallin M, Rizzoni D, Bova S, Mazzocchi G, Agabiti-Rosei E, et al. Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor. J Hypertens 2002; 20:1451-1459.